The results showed that SELENOF KO caused glucose metabolism disorders only in young mice, especially in 12-week-old mice, characterized by hyperglycemia, serum insulin reduction, impaired glucose tolerance, decreased insulin sensitivity, decreased glucose catabolism, increased gluconeogenesis and impaired AKT signaling pathways. Here, AKT1 is linked to glucose metabolism disease.